<?xml version="1.0" encoding="UTF-8"?>
			<!DOCTYPE ijpp.edwiserinternational.com [
<!ELEMENT channel (title,link,description,language,managingEditor,webMaster,copyright,image,item,item,item,item,item,item)>
<!ELEMENT title (#PCDATA)>
<!ELEMENT link (#PCDATA)>
<!ELEMENT language (#PCDATA)>
<!ELEMENT managingEditor (#PCDATA)>
<!ELEMENT webMaster (#PCDATA)>
<!ELEMENT copyright (#PCDATA)>

<!ELEMENT image (title,link,url,width,height)>
<!ELEMENT url (#PCDATA)>
<!ELEMENT width (#PCDATA)>
<!ELEMENT height (#PCDATA)>

<!ELEMENT item (title,pubDate,link,author,comments,category,description)>
<!ELEMENT pubDate (#PCDATA)>
<!ELEMENT author (#PCDATA)>
<!ELEMENT comments (#PCDATA)>
<!ELEMENT category (#PCDATA)>
<!ELEMENT description (#PCDATA)>

]>
		<channel>
<title>Journal-of-Pharmaceutical-Research-Science-Technology-ISSUE VOLUME Volume 4 ISSUE Issue 1</title>
<link>http://ijpp.edwiserinternational.com/rss-feed.php</link>
<description>
Journal-of-Pharmaceutical-Research-Science-Technology: VOLUME Volume 4 ISSUE Issue 1, Jan-June 2020
</description>
<language>en-us</language>
<managingEditor>editor@edwiserinternational.com</managingEditor>
<webMaster>editor@edwiserinternational.com</webMaster>
<copyright>editor@edwiserinternational.com</copyright>
<image>
<title>Journal-of-Pharmaceutical-Research-Science-Technology-ISSUE VOLUME Volume 4 ISSUE Issue 1</title>
<link>http://ijpp.edwiserinternational.com/rss-feed.php</link>
<url>http://ijpp.edwiserinternational.com/img/logo1.png</url>
<width>360</width>
<height>109</height>
</image><item>
		<title>Antibiotic-Prescribing-Patterns-in-Paediatric-Patients-at-Levy-Mwanawasa-University-Teaching-Hospital-in-Lusaka-Zambia</title>
		<pubDate>24-Feb-2020</pubDate>
<link>http://ijpp.edwiserinternational.com/admin/uploads/By1sQb.pdf</link>
		<author>Kalonga-J-Hangoma-J-Banda-M-et-al-</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[The use of antimicrobial agents has become a routine practice for the treatment of paediatric illnesses. The uncontrolled use of antibiotics has caused a rise in antimicrobial resistance. This study aimed to assess the antibiotic prescribing patterns in paediatric patients at Levy Mwanawasa University Teaching Hospital in Lusaka, Zambia. This was a cross-sectional study conducted between April 2019 to July 2019. The study population included both in-patients and out-patients aged between one month and eighteen years whose medical files were reviewed. A sample size of 357 medical files was conveniently sampled. Statistical Package for Social Sciences version 21.0 was used for data analysis. A chi-square test was used to assess the association between categorical variables. A p]]>}</description>
		</item><item>
		<title>Intracellular-Pharmacokinetics-of-PARP-Inhibitors-in-Breast-and-Ovarian-Cancer-Cells-and-Correlation-to-Drug-Action-A-Review</title>
		<pubDate>11-Mar-2020</pubDate>
<link>http://ijpp.edwiserinternational.com/admin/uploads/8bUvKA.pdf</link>
		<author>Phiri-M-Duo-L-Tengfei-L-et-al-</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[Recently Poly (ADP-Ribose) Polymerase inhibitor (PARPi) drugs were approved by the FDA for clinical use in breast and ovarian cancer, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Olaparib an oral formulation approved for the treatment of patients with BRCA mutation and recurrent ovarian cancer; has shown to provide clinically significant benefit. Inhibition of PARP results in accumulation of single-strand breaks, leading to formation of double-strand breaks. Olaparib, a small molecule, selectively binds and inhibits Poly (ADP-Ribose) Polymerase enzyme, inhibiting its mediated repair of single-strand DNA breaks. Poly (ADP-Ribose) Polymerase inhibition enhances cytotoxicity of DNA damaging agents and reverses tumor cell chemoresistance and radio resistance. There has been limited research on the quantification of anti-cancer drugs intracellularly; very few studies have attempted to quantify Olaparib intracellularly. For the first time, intercellular quantification of PARP inhibitor was reported in two studies involving oral dosage form and the other nano-delivery system, allowing for quantification of Olaparib distribution in the nuclei, cytoplasm, liver, kidney, plasma, and urine. This review, covers articles and reports from 1992 to 2019 and is aimed at highlighting the increasing importance of intracellular quantification of anti-cancer drugs using PARP inhibitors as examples, due to limited research done on this group of drugs, only Olaparib has been reported have been determined intracellularly.]]>}</description>
		</item><item>
		<title>Coronavirus-COVID-19-History-Current-Knowledge-and-Pipeline-Medications</title>
		<pubDate>31-Mar-2020</pubDate>
<link>http://ijpp.edwiserinternational.com/admin/uploads/yFhJfm.pdf</link>
		<author>Jahangir-MA-Muheem-A-Rizvi-MF</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[In spite of being characterised in the 1960s, human coronavirus still needs extensive studying for its better understanding. Since, the start of the new millennium corona viruses had caused pandemic. SARS-CoV and MERS-CoV were the first coronavirus outbreak which has resulted in socioeconomic and psychological losses in the past. The novel corona virus outbreak (COVID-19) needs lesson from our past experience in tackling the devastating situation. The population needs awareness about this novel virus during the current pandemic situation. In this article the author reviews the history of coronaviruses, its lifecycle and genomic structure, current pandemic situation, diagnosis of COVID-19, preventive measures, current medication and pipeline drugs and diagnostic kits.]]>}</description>
		</item><item>
		<title>Letter-to-Editor-Coronavirus-Disease-COVID-19-A-Global-Health-Problem</title>
		<pubDate>13-Apr-2020</pubDate>
<link>http://ijpp.edwiserinternational.com/admin/uploads/hjaR8z.pdf</link>
		<author>Steward-Mudenda</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[Novel Coronavirus disease 2019 (COVID-19) is a respiratory tract infectious disease that is caused by a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), provisionally called the 2019 novel coronavirus (2019-nCoV). COVID-19 is a newly identified pathogen and thus termed as a novel coronavirus disease. COVID-19 causes Severe Acute Respiratory Syndrome (SARS) and was declared a global pandemic by the World Health Organization on 11th March 2020. COVID-19 was first reported on 31st December 2019 in Wuhan, China, and was initially referred to as pneumonia of unknown etiology.]]>}</description>
		</item><item>
		<title>Letter-to-Editor-Steps-and-Measure-to-Stop-the-Spread-of-COVID-19</title>
		<pubDate>13-Apr-2020</pubDate>
<link>http://ijpp.edwiserinternational.com/admin/uploads/Gn0IAH.pdf</link>
		<author>Mohammed-Irfan</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[The coronavirus (Covid-19) falls into the category of viruses that may cause numerous symptoms of which the most common ones are fever, tiredness and dry cough. Severe symptoms include lung infection and difficulty in breathing. Elderly people who are having other comorbid diseases such as asthma, diabetes, or heart disease are the most vulnerable towards corona infection. On 29th December 2019 in Wuhan city of China, the first case of novel coronavirus was reported. The virus was found to affect the lower respiratory tract of patients. This virus was called 2019 novel coronavirus or the COVID-19 by World Health Organization.]]>}</description>
		</item><item>
		<title>Coronavirus-Disease-2019-COVID-19-The-Role-of-Pharmacists-in-the-Fight-against-COVID-19-Pandemic</title>
		<pubDate>12-May-2020</pubDate>
<link>http://ijpp.edwiserinternational.com/admin/uploads/xNK3Ow.pdf</link>
		<author>Phiri-MN-Banda-M-Mudenda-S-et-al-</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[Coronavirus Disease 2019 (COVID-19) is a viral infection that affects the respiratory system [1,2]. The history of human coronaviruses can be dated to as early as 1965 when scientists were able to isolate the virus from the human respiratory tract who had suffered from colds.]]>}</description>
		</item></channel>